3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 2/3
1
Status
Recruiting
3
Unknown
1
Terminated
1
Completed
1
Sponsor Class
OTHER
3
Study Type
Interventional
2
Observational
1
Sponsor
Cancer Type
NET
3
Endocrine
3
Gastrointestinal
2
Conditions
Neuroendocrine Tumors
3
Gastro-enteropancreatic neuroendocrine tumor
1
Carcinoma, Neuroendocrine
1
Interventions
lutetium Lu 177 dotatate
15
Magnetic Resonance Spectroscopy
9
Everolimus
8
gallium Ga 68 dotatate
6
lanreotide
4
cabozantinib
4
Temozolomide
4
Specimen Handling
4
Nivolumab
4
Lutetium-177
4
Lutetium
4
177Lu-octreotide, DOTA(0)-Tyr(3)-
4
surufatinib
3
olaparib
3
copper dotatate CU-64
3
Somatostatin
3
Injections
3
Ga(III)-DOTATOC
3
Fluorodeoxyglucose F18
3
Cyclophosphamide
3
Capecitabine
3
pembrolizumab
2
fludarabine phosphate
2
fludarabine
2
amino-acid, glucose, and electrolyte solution
2
X-Rays
2
Sunitinib
2
Radiosurgery
2
Octreotide
2
Drug Therapy
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Recruiting
×
Somatostatin
×
NET
×
Clear all
NCT04464122
2025-04-03
REBORN
University of Roma La Sapienza
Recruiting
60 enrolled
NCT06855095
2025-03-03
ATSA
The Netherlands Cancer Institute
Phase 2/3
Recruiting
39 enrolled
NCT05701241
2024-06-14
SAUNA
University Hospital, Antwerp
Phase 4
Recruiting
270 enrolled